# Glycemic Velocity and Early Retinal Microvascular Change With GLP-1RA Versus SGLT2i Initiation in Type 2 Diabetes (GLIDE)

> **NCT07723820** · — · NOT_YET_RECRUITING · sponsor: **Thammasat University Hospital** · enrollment: 126 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus
- Diabetic Retinopathy (DR)

## Interventions

- **DRUG:** GLP-1 Receptor Agonists
- **DRUG:** SGLT2 inhibitor

## Key facts

- **NCT ID:** NCT07723820
- **Lead sponsor:** Thammasat University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2026-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07723820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07723820, "Glycemic Velocity and Early Retinal Microvascular Change With GLP-1RA Versus SGLT2i Initiation in Type 2 Diabetes (GLIDE)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07723820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*